Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.63 [0.6, 0.66]
764 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.54 [0.5, 0.6]
1465 participants
High
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
RR 2.47 [2.01, 3.04]
1465 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 0.7 [0.54, 0.91]
1465 participants
Low
Overall survival† · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.81 [0.65, 1.01]
1157 participants
Low
Intervention not reported
Comparative studies · children and adolescents aged 18 years and under diagnosed with ADHD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD
It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐comparative studies · children and adolescents aged 18 years and under diagnosed with ADHD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review